Alizyme Share Discussion Threads

[gilbertd] 24/2/2010 09:06

ant15 - so the administrators fee is going to soak up ALL of the surplus cash? How nice for them.

[ant15] 22/2/2010 15:47

I spoke to the joint receivers too I hold nearly 500,000 shares and have taken a big hit here They do not imagine any money will be paid out to shareholders was my read. I did find this somewhat surprising as the individula candidates were valued at far more and further they could be sold into domains not globally potentially for more money. I suppose the right tack here is dont hold your breathe.As regards the shell one could take it out of administration but it would not be worth unless all the shareholders were prepared to take part in an open offer to raise money BUT for what!!

[uptick] 21/2/2010 11:15

Thanks for the info gilbertd... :(

[gilbertd] 19/2/2010 09:19

uptick - there could be a small payout to shareholders once the administrators have taken their obscenely large fee out of the pot.

"
Administration of Alizyme Plc and Alizyme Therapeutics Limited: Update

Dated: Monday 19 October 2009

Comment from Ian Carr, Joint Administrator of Alizyme plc and Alizyme Therapeutics Limited

"Further to the announcement on Friday 16th October of the sale of cetilistat to Norgine BV and dividend prospects for shareholders, it should be noted that the Statement of Affairs of Alizyme plc included in the administrators' proposals dated 17 September 2009 reflected the position of that company and the directors' best estimates of the realisable value of the assets at the time it went in to administration. As stated in the announcement any future dividend potentially available to shareholders will be subject to the adjudication of creditors claims. Claims will be adjudicated by a subsequently appointed liquidator of each of Alizyme plc and Alizyme Therapeutics Limited and will also be subject to any tax payable and costs of realisation."

Grant Thornton UK LLP is a leading financial and business adviser with 30 locations nationwide. We are the UK member of Grant Thornton International, one of the world's leading international organisations of independently owned and managed accounting and consulting firms. Although Grant Thornton International is not a worldwide partnership, the firms share a commitment to providing the same high quality service to their clients wherever they do business.

Copyright © 2009 Grant Thornton UK LLP. All rights reserved.

Grant Thornton - advisers to the independently minded – www.grantthornton.co.uk

Back
"

[uptick] 17/2/2010 19:27

I currently still hold 6000 AZM shares. My broker, iDealing, emailed me today with 2 options

1) To charge me £15 to send me my holding in certificated form OR

2) TO 'gift' the shares to iDealing.

As AZM has delisted the possibility of a reverse T/O into the shell doesn't exist.

My question, is it worth holding these in unquoted form? For example, could disposal of IP lead to any compensation?

Thanks in advance.

Uptick

[tim mcliar] 15/2/2010 13:33

Yes thanks.

The management did very well.

Great salaries, amazing performance bonuses, wonderful pensions and all without ever showing a penny profit on the balance sheet.

Shafted the shareholders good but thats what shareholders are for.

Amazing what you can get away with. What a game heh.

[riskier] 04/2/2010 14:24

No, not yet!!

[wig4] 04/2/2010 14:18

Has anyone received any cash yet?

[tim mcliar] 27/12/2009 11:02

Happy Christmas shareholders.

[dunderheed] 07/12/2009 12:44

# 212

You can't hide 'good' breeding imo.

[snoppity] 06/12/2009 02:02

Hmmm.

This is the problem with this whole web discussion thing. Unpleasant gloating is totally uncalled for. Not that one should take this last poisonous contribution seriously.

Good luck to all! I shall spend a happy Christmas, chastened and poorer for investing in this company, but spiritually and physically healthy. I wish all contributers a very happy festive season!

Snops

[billthebank] 04/11/2009 00:21

I thought this was a wind up!!!!!!!! I just can't believe it. I am really glad I didn't lose all my original investment. In the end had lost around 31K so could have been worse. Mind u I sed the same thing about MDZ should know better. Two down 2 to go HML & SAR & that will take the biscuit. Will ne of them come in. No idea any more. Patience may see me appropriately rwarded. Bios PAH!!!!

[loafofbread] 03/11/2009 09:13

Takeda / Amylin
Published: November 2 2009 09:30 | Last updated: November 2 2009 23:02

The battle against the bulge has attracted a new heavyweight. Takeda Pharmaceutical's plan to develop obesity drugs with Amylin Pharmaceutical, a US biotechnology group, is the latest twist in Japanese drugmakers' search for new growth.

The companies are natural partners. Amylin has a record of sorts in obesity, which the World Health Organisation estimates will affect 700m people by 2015. Weight loss is a beneficial side-effect of Byetta, a diabetes drug Amylin sells in partnership with Eli Lilly, a fellow US drugmaker. Takeda, Japan's biggest drugmaker by turnover, has a big sales force but craves its counterpart's research pipeline. Takeda also has ample cash to fund costlier late-stage clinical trials.

EDITOR'S CHOICE
Shire's drug sales offset Adderall decline - Oct-30AZ to settle US marketing case - Oct-29GSK steps along desired path of evolution - Oct-28Ranbaxy suffers 53% fall in US sales - Oct-26Goldshield bid battle hots up - Oct-26J&J wants deals with rivals to share risk - Oct-25The deal's small upfront payment should please Takeda's shareholders, still smarting after the Japanese group last year shelled out $8.8bn – 70 times prospective earnings – for US cancer specialist Millennium Pharmaceuticals. For an initial outlay of $75m, Takeda gains access to Amylin's pipeline of obesity drugs, including a couple in phase two trials – not bad, considering it costs $70m on average to bring a new drug to the end of phase two. Just getting there costs an average of $32m.

Things become more expensive from there. Takeda will pay 80 per cent of the cost of clinical trials in the US, and 100 per cent of development costs elsewhere. Amylin could reap substantially more if the new drugs pass certain development and sales hurdles. Takeda will also pay Amylin "double-digit" royalties on global sales of approved drugs. Takeda's shareholders may not relish splitting profits with a US rival but, with patent expirations looming and drug industry profits falling anyway, they will be happy enough if the result is less dependence on Japan's moribund domestic drugs market.

[dunderheed] 02/11/2009 17:18

Absolutely - but I (probably) will buy shares in any quoted company he becomes involved in - merely to attend the agm and ask him these questions then!!
I say probably because I am known to make such 'promises' then never bother to do sod all!!

[capricious] 02/11/2009 17:14

I don't doubt you did, and also that he mislead you, but without public record he could basically lie, which is unfortunate since many have lost money, including myself.

[dunderheed] 02/11/2009 16:57

No I (very) specifically requested cash-flow clarifications and he specifically told me I had nothing to worry about.

[capricious] 02/11/2009 16:56

Thats probably why he mislead you, even if you had recorded them, its inadmissible if he was not aware of it.

[dunderheed] 02/11/2009 16:53

Rod - he definitely mis-led me in private phone calls.

[rod boner] 02/11/2009 16:40

Does anyone know -

Have all the rights to Cetilistat been sold to Norgine?

Have AZM retained the Japanese rights, which could pay out £millions next year?

Why only £4m for Cetilistat, if the Japanese trials report in 2010 and could pay-out loads more money.

Are the Administrators trying to sell ATL-104?

Why are the Administrators not now relisting Alizyme if the business now has another £4m from the Cetilistat sale?

How much was Tim McC's leaving figure?

Anyone think he mislead shareholders?

[the_doctor] 02/11/2009 12:34

They clearly didnt see ex-Japan rights to ceti as a good investment

Why? because the trial costs are high, the product doesnt do much and orlistat will be off patent.

Look around and you'll see more promising compounds getting the attention.

[jak1] 02/11/2009 12:29

Yep, that tickled me NOT...

[dunderheed] 02/11/2009 11:59

Just for a laugh!
Takeda signs obesity deal with Amylin worth over $1 billion
02 November 2009

[dunderheed] 19/10/2009 16:07

Cheers gilbert!

[gilbertd] 19/10/2009 16:04

Just received this:

"Further to the announcement on Friday 16th October of the sale of cetilistat to Norgine BV and dividend prospects for shareholders, it should be noted that the Statement of Affairs of Alizyme plc included in the administrators' proposals dated 17 September 2009 reflected the position of that company and the directors' best estimates of the realisable value of the assets at the time it went in to administration. As stated in the announcement any future dividend potentially available to shareholders will be subject to the adjudication of creditors claims. Claims will be adjudicated by a subsequently appointed liquidator of each of Alizyme plc and Alizyme Therapeutics Limited and will also be subject to any tax payable and costs of realisation.."